Guardant Health, Inc. (GH) vs IDEXX Laboratories, Inc. (IDXX)

Guardant Health, Inc. and IDEXX Laboratories, Inc. are both Diagnostics & Research companies. IDEXX Laboratories, Inc. is the larger, with a market value of $40.2B against $23.9B — 1.7× the size. Guardant Health, Inc. has negative trailing earnings, so its P/E is not meaningful; IDEXX Laboratories, Inc. trades at 36.2×. Guardant Health, Inc. grew revenue faster over the last twelve months: 42.7% against 12.8%. IDEXX Laboratories, Inc. has the higher net margin (25.0% vs −38.3%) and the higher return on invested capital (48.9% vs −129.7%). Across the 18 metrics below, IDEXX Laboratories, Inc. leads on 11 and Guardant Health, Inc. on 7.

Valuation

Metric GH IDXX Diagnostics & Research median
P/E n/m 36.24 33.95
P/S 19.91 9.00 4.87
P/B n/m 25.42 3.12
Price to free cash flow n/m 33.14 34.02
EV/EBITDA n/m 25.58 25.20
EV/Sales 20.29 9.06 5.66
Earnings yield (1.97%) 2.76% (1.75%)
Free cash flow yield (1.10%) 3.02% (0.13%)

Profitability

Metric GH IDXX Diagnostics & Research median
Gross margin 65.01% 62.45% 50.89%
Operating margin (39.75%) 32.03% (8.57%)
Net margin (38.33%) 25.03% (6.37%)
Free cash flow margin (20.35%) 27.17% 0.00%
Return on equity 171.64% 74.21% (2.92%)
Return on assets (27.95%) 33.65% (6.71%)
Return on invested capital (129.70%) 48.87% 0.00%

Growth

Metric GH IDXX Diagnostics & Research median
Revenue growth (TTM) 42.74% 12.77% 7.69%
EPS growth (last fiscal year) 6.74% 22.59% —
Revenue growth, 5-year CAGR 27.92% 9.72% 7.40%
Net income growth, 5-year CAGR 0.00% 12.74% 0.00%

Health

Metric GH IDXX Diagnostics & Research median
Debt to equity (6.74) 0.28 0.11
Current ratio 4.03 1.17 2.02
Net debt to EBITDA (0.75) 0.18 0.78

Dividend

Metric GH IDXX Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio 0.00 0.00 0.00

Size

Metric GH IDXX Diagnostics & Research median
Market cap 23.94b 40.18b 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack